Document 2893
 DOCN  M94A2893
 TI    Treatment with intravenous immunoglobulin in severe Guillain-Barre
       syndrome and HIV infection.
 DT    9412
 AU    Rodriguez Arrondo F; Huarte I; Von Wichmann MA; Iribarren JA;
       Arrizabalaga J; Urtasun M; Infectious Diseases Unit, Hospital Ntra Sra
       Aranzazu, San; Sebastian, Spain.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):200 (abstract no. PB0228). Unique
       Identifier : AIDSLINE ICA10/94369682
 AB    OBJECTIVE: To determine the Efficacy and safety of High-dose intravenous
       immunoglobulin in the treatment of severe Guillain-Barre syndrome (GBS)
       in patients with HIV infection. METHODS: Two severely affected patients
       were treated with five doses of a preparation of immunoglobulin (0.4 g
       per kilogram daily). Treatment was started within 2 weeks after onset.
       Clinical improvement and drug toxicity were evaluated by recovery time,
       neurological scores and vital capacity and drug toxicity. RESULTS:
       Clinical response was excellent in both patients receiving intravenous
       immunoglobulin; their neurologic disability score and vital capacity
       improved within a few days. There was no recurrence during follow up
       periods of 12 months. No side-effects were noted. CONCLUSION:
       Immunoglobulin is a practical, safe and effective treatment for GBS and
       HIV infection. We believe that High-dose intravenous immunoglobulin
       should be the first choice of therapy in severe illness. Further
       experience in larger number of patients is necessary.
 DE    Drug Evaluation  Human  HIV Infections/*COMPLICATIONS  Immunoglobulins,
       Intravenous/*THERAPEUTIC USE
       Polyradiculoneuritis/COMPLICATIONS/*THERAPY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).